An observational study «FOLLITROPIN» comparing the efficacy of follitropin alpha biosimilar: the real-world data

Introduction. The efficacy and safety of biosimilar follitropin alpha have been demonstrated in randomized blinded prospective clinical trials of phases I and III. Unfortunately, there is a gap between the clinical trials and real clinical practice data. The real-world patient data helps to create a...

Full description

Saved in:
Bibliographic Details
Main Authors: D. P. Kamilova, M. M. Ovchinnikova, E. Sh. Ablyaeva, M. M. Leviashvili, N. S. Stuleva, E. V. Broitman, M. A. Ganikhina, E. N. Mayasina, L. F. Iskhakova, K. Yu. Boyarskiy, E. N. Ovsyannikova, Z. B. Barakhoeva, S. V. Nikitin, I. A. Bendusov, Yu. A. Fetisova, M. A. Yudina, E. S. Tararashkina, D. T. Khetagurova, D. V. Blinov, M. A. Polzikov
Format: Article
Language:Russian
Published: IRBIS LLC 2021-03-01
Series:Акушерство, гинекология и репродукция
Subjects:
Online Access:https://www.gynecology.su/jour/article/view/920
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849249229334118400
author D. P. Kamilova
M. M. Ovchinnikova
E. Sh. Ablyaeva
M. M. Leviashvili
N. S. Stuleva
E. V. Broitman
M. A. Ganikhina
E. N. Mayasina
L. F. Iskhakova
K. Yu. Boyarskiy
E. N. Ovsyannikova
Z. B. Barakhoeva
S. V. Nikitin
I. A. Bendusov
Yu. A. Fetisova
M. A. Yudina
E. S. Tararashkina
D. T. Khetagurova
D. V. Blinov
M. A. Polzikov
author_facet D. P. Kamilova
M. M. Ovchinnikova
E. Sh. Ablyaeva
M. M. Leviashvili
N. S. Stuleva
E. V. Broitman
M. A. Ganikhina
E. N. Mayasina
L. F. Iskhakova
K. Yu. Boyarskiy
E. N. Ovsyannikova
Z. B. Barakhoeva
S. V. Nikitin
I. A. Bendusov
Yu. A. Fetisova
M. A. Yudina
E. S. Tararashkina
D. T. Khetagurova
D. V. Blinov
M. A. Polzikov
author_sort D. P. Kamilova
collection DOAJ
description Introduction. The efficacy and safety of biosimilar follitropin alpha have been demonstrated in randomized blinded prospective clinical trials of phases I and III. Unfortunately, there is a gap between the clinical trials and real clinical practice data. The real-world patient data helps to create an evidence-based background for successful implementation of medicine at everyday practice in a nonselected population.Aim: to investigate the efficacy of follitropin alpha biosimilar therapy (Primapur®) in nonselected real-world population.Materials and Methods. A retrospective observational anonymized cohort study of follitropin alpha biosimilar (Primapur®) as a pre-filled pen injector with a dose adjustment of 5 IU, aimed to investigate its efficacy and safety in a nonselected population with indications to assisted reproductive technologies (ART) was carried out. The ovarian stimulation (OS) protocols included: monotherapy protocols with using only Primapur®; mixed protocols (recombinant and urinary-derived gonadotropins); short protocols with using antagonists of gonadotropin-releasing hormone (GnRH) and long protocols with GnRH agonists. The stimulation protocols were analyzed with Primapur® application for at least 5 days.Results. The overall clinical efficacy of ovarian stimulation cycles (N = 5484) was: oocytes retrieved - 9.5 ± 7.2, mature (MII) - 6.8 ± 6.6, fertilized (2PN) - 6.1 ± 5.8, clinical pregnancy per ET (PR) - 38.4 %. Mixed gonadotropin protocols (N = 2625) vs. monotherapy with Primapur® (N = 2859): oocytes retrieved - 8.6 ± 6.8 vs. 10.3 ± 7.4 (p < 0.001), mature (MII) - 6.7 ± 6.2 vs. 7.7 ± 6.9 (p < 0.001), fertilized (2PN) - 5.8 ± 5.2 vs. 7.2 ± 6.2 (p < 0.001). There were statistically significant differences between oocyte yields in mixed vs. monotherapy protocols due to subgroup differences, including age, body mass index (BMI) and IVF/ICSI attempts. No statistically significant differences were found for PR: 39.3 % vs. 37.6 % (p = 0.314). Monotherapy protocols with GnRH antagonist OS (N = 2183) vs. GnRH agonist (N = 676) revealed: oocytes retrieved - 10.5 ± 7.5 vs. 9.6 ± 7.0 (p = 0.032), mature (MII) - 7.6 ± 6.9 vs. 6.7 ± 5.7 (p < 0.001), fertilized (2PN) - 7.3 ± 6.3 vs. 5.7 ± 5.0 (p < 0.001). There were statistically significant differences between BMI and IVF/ICSI attempts. No statistically significant differences were found for PR: 37.9 % vs. 35.9 % (p = 0.482). All medicines were well tolerated and no serious adverse reactions were reported.Conclusion. This was the largest retrospective observational study conducted in the field of fertility in Russia and involved 5484 ovarian stimulation protocols at 35 IVF clinics. The obtained results demonstrated similar clinical efficacy for follitropin alpha biosimilar Primapur® in different OS protocols in real clinical practice.
format Article
id doaj-art-661588ba396143dda53bf2d9330f5c39
institution Kabale University
issn 2313-7347
2500-3194
language Russian
publishDate 2021-03-01
publisher IRBIS LLC
record_format Article
series Акушерство, гинекология и репродукция
spelling doaj-art-661588ba396143dda53bf2d9330f5c392025-08-20T03:57:39ZrusIRBIS LLCАкушерство, гинекология и репродукция2313-73472500-31942021-03-0115152110.17749/2313-7347/ob.gyn.rep.2021.212624An observational study «FOLLITROPIN» comparing the efficacy of follitropin alpha biosimilar: the real-world dataD. P. Kamilova0M. M. Ovchinnikova1E. Sh. Ablyaeva2M. M. Leviashvili3N. S. Stuleva4E. V. Broitman5M. A. Ganikhina6E. N. Mayasina7L. F. Iskhakova8K. Yu. Boyarskiy9E. N. Ovsyannikova10Z. B. Barakhoeva11S. V. Nikitin12I. A. Bendusov13Yu. A. Fetisova14M. A. Yudina15E. S. Tararashkina16D. T. Khetagurova17D. V. Blinov18M. A. Polzikov19GC «Mother and Child»GC «Mother and Child»GC «Mother and Child»GC «Mother and Child»Sechenov University; Center of Reproductive Medicine and Genetics «Nova Clinic»GC «Mother and Child»GC «Mother and Child»Clinical Institute of Reproductive MedicineGC «Mother and Child»«GENESIS» Reproduction Centre; Mechnikov North-Western State Medical University, Health Ministry of Russian FederationGC «Mother and Child»«AltraVita» Human Reproduction ClinicGC «Mother and Child»GC «Mother and Child»GC «Mother and Child»GC «Mother and Child»GC «Mother and Child»Pirogov Russian National Research Medical University, Health Ministry of Russian FederationMD Medical Group; Institute for Preventive and Social MedicineIVFarma LLCIntroduction. The efficacy and safety of biosimilar follitropin alpha have been demonstrated in randomized blinded prospective clinical trials of phases I and III. Unfortunately, there is a gap between the clinical trials and real clinical practice data. The real-world patient data helps to create an evidence-based background for successful implementation of medicine at everyday practice in a nonselected population.Aim: to investigate the efficacy of follitropin alpha biosimilar therapy (Primapur®) in nonselected real-world population.Materials and Methods. A retrospective observational anonymized cohort study of follitropin alpha biosimilar (Primapur®) as a pre-filled pen injector with a dose adjustment of 5 IU, aimed to investigate its efficacy and safety in a nonselected population with indications to assisted reproductive technologies (ART) was carried out. The ovarian stimulation (OS) protocols included: monotherapy protocols with using only Primapur®; mixed protocols (recombinant and urinary-derived gonadotropins); short protocols with using antagonists of gonadotropin-releasing hormone (GnRH) and long protocols with GnRH agonists. The stimulation protocols were analyzed with Primapur® application for at least 5 days.Results. The overall clinical efficacy of ovarian stimulation cycles (N = 5484) was: oocytes retrieved - 9.5 ± 7.2, mature (MII) - 6.8 ± 6.6, fertilized (2PN) - 6.1 ± 5.8, clinical pregnancy per ET (PR) - 38.4 %. Mixed gonadotropin protocols (N = 2625) vs. monotherapy with Primapur® (N = 2859): oocytes retrieved - 8.6 ± 6.8 vs. 10.3 ± 7.4 (p < 0.001), mature (MII) - 6.7 ± 6.2 vs. 7.7 ± 6.9 (p < 0.001), fertilized (2PN) - 5.8 ± 5.2 vs. 7.2 ± 6.2 (p < 0.001). There were statistically significant differences between oocyte yields in mixed vs. monotherapy protocols due to subgroup differences, including age, body mass index (BMI) and IVF/ICSI attempts. No statistically significant differences were found for PR: 39.3 % vs. 37.6 % (p = 0.314). Monotherapy protocols with GnRH antagonist OS (N = 2183) vs. GnRH agonist (N = 676) revealed: oocytes retrieved - 10.5 ± 7.5 vs. 9.6 ± 7.0 (p = 0.032), mature (MII) - 7.6 ± 6.9 vs. 6.7 ± 5.7 (p < 0.001), fertilized (2PN) - 7.3 ± 6.3 vs. 5.7 ± 5.0 (p < 0.001). There were statistically significant differences between BMI and IVF/ICSI attempts. No statistically significant differences were found for PR: 37.9 % vs. 35.9 % (p = 0.482). All medicines were well tolerated and no serious adverse reactions were reported.Conclusion. This was the largest retrospective observational study conducted in the field of fertility in Russia and involved 5484 ovarian stimulation protocols at 35 IVF clinics. The obtained results demonstrated similar clinical efficacy for follitropin alpha biosimilar Primapur® in different OS protocols in real clinical practice.https://www.gynecology.su/jour/article/view/920follitropin alpharecombinant follicle-stimulating hormonefshbiosimilarin vitro fertilizationivfassisted reproductive technologiesart
spellingShingle D. P. Kamilova
M. M. Ovchinnikova
E. Sh. Ablyaeva
M. M. Leviashvili
N. S. Stuleva
E. V. Broitman
M. A. Ganikhina
E. N. Mayasina
L. F. Iskhakova
K. Yu. Boyarskiy
E. N. Ovsyannikova
Z. B. Barakhoeva
S. V. Nikitin
I. A. Bendusov
Yu. A. Fetisova
M. A. Yudina
E. S. Tararashkina
D. T. Khetagurova
D. V. Blinov
M. A. Polzikov
An observational study «FOLLITROPIN» comparing the efficacy of follitropin alpha biosimilar: the real-world data
Акушерство, гинекология и репродукция
follitropin alpha
recombinant follicle-stimulating hormone
fsh
biosimilar
in vitro fertilization
ivf
assisted reproductive technologies
art
title An observational study «FOLLITROPIN» comparing the efficacy of follitropin alpha biosimilar: the real-world data
title_full An observational study «FOLLITROPIN» comparing the efficacy of follitropin alpha biosimilar: the real-world data
title_fullStr An observational study «FOLLITROPIN» comparing the efficacy of follitropin alpha biosimilar: the real-world data
title_full_unstemmed An observational study «FOLLITROPIN» comparing the efficacy of follitropin alpha biosimilar: the real-world data
title_short An observational study «FOLLITROPIN» comparing the efficacy of follitropin alpha biosimilar: the real-world data
title_sort observational study follitropin comparing the efficacy of follitropin alpha biosimilar the real world data
topic follitropin alpha
recombinant follicle-stimulating hormone
fsh
biosimilar
in vitro fertilization
ivf
assisted reproductive technologies
art
url https://www.gynecology.su/jour/article/view/920
work_keys_str_mv AT dpkamilova anobservationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT mmovchinnikova anobservationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT eshablyaeva anobservationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT mmleviashvili anobservationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT nsstuleva anobservationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT evbroitman anobservationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT maganikhina anobservationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT enmayasina anobservationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT lfiskhakova anobservationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT kyuboyarskiy anobservationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT enovsyannikova anobservationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT zbbarakhoeva anobservationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT svnikitin anobservationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT iabendusov anobservationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT yuafetisova anobservationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT mayudina anobservationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT estararashkina anobservationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT dtkhetagurova anobservationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT dvblinov anobservationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT mapolzikov anobservationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT dpkamilova observationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT mmovchinnikova observationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT eshablyaeva observationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT mmleviashvili observationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT nsstuleva observationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT evbroitman observationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT maganikhina observationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT enmayasina observationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT lfiskhakova observationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT kyuboyarskiy observationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT enovsyannikova observationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT zbbarakhoeva observationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT svnikitin observationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT iabendusov observationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT yuafetisova observationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT mayudina observationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT estararashkina observationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT dtkhetagurova observationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT dvblinov observationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata
AT mapolzikov observationalstudyfollitropincomparingtheefficacyoffollitropinalphabiosimilartherealworlddata